CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Nova Mentis Life Science
Stock Performance

CSE FSE

Nova Mentis Autism Clinical Study

 

Sign up to learn more

Latest News

Nova Mentis Provides Corporate Update - 2022 Planned Catalysts

Vancouver, British Columbia – January 12, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders reviews its 2021 drug development accomplishments and its planned 2022 steps towards drug approval and commercialization.

 

Nova Mentis Welcomes New CFO Rebecca Hudson

Vancouver, British Columbia – December 31, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce Rebecca Hudson has joined NOVA as its Chief Financial Officer, adding corporate finance, accounting and risk management experience to the Company’s management team.